Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin
Status:
Recruiting
Trial end date:
2024-07-15
Target enrollment:
Participant gender:
Summary
The Valeria trial will provide high-quality evidence regarding the efficacy and safety of
oral rivaroxaban in thromboprophylaxis after gynecological pelvic cancer surgery in
comparison with standard parenteral enoxaparin.